Recent calls for reforming the regulatory environment for the development of fixed combinations of drugs have ignored such products' long and checkered history, including their role in the creation of FDA requirements. This history is instructive in the current context.
No takes yet. Share an insight, caveat, or question.
Podolsky et al. (2011) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: